Overview
Investors searching USTB vs INJ usually want a clear market-cap and momentum snapshot. USTB prints $1,865.83 (+0.00%) while Injective is at $5.02 (+1.64%), with volume edge currently on Injective.
Quick winners
Full comparison
| Metric | USTB | INJ |
|---|---|---|
| Price | $1,865.83 | $5.02 |
| Market Cap | $892.66M | $490.41M |
| FDV | — | — |
| Volume 24h | $0.000000 | $2.97M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 71.00 | 99.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +3.50% | +5.78% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | USTB | INJ |
|---|---|---|
| 1H | — | — |
| 24H | +0.00% | +1.64% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | USTB | INJ |
|---|---|---|
| RSI | 54.31 | 53.92 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 66.45 | 0.29 |
| ADX | 20.44 | 12.69 |
| Support | 1,827.82 | 4.91 |
| Resistance | 1,960.30 | 5.47 |
| Trend | bearish | neutral |
| Momentum | 60.00 | — |
| Signal | neutral | neutral |
Automatic technical analysis
Relative technical health favors reading both charts side by side. AI scores (58.20 vs 48.70) summarize PEPS modules, but supports and resistances still decide invalidation.
Fundamentals
| Metric | USTB | INJ |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | — | 0.00 |
| Github activity | — | 118.00 |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
USTB
Injective
Pros and cons
Pros of USTB
- Higher ranking for USTB can translate into tighter spreads on major venues.
- Market-cap scale on USTB may dampen some idiosyncratic shocks versus smaller peers.
- Composite PEPS readings for USTB can surface clearer module agreement during trend phases.
Cons of USTB
- When dominance narratives fade, USTB can lag hotter rotation names.
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
- Regulatory or macro headlines can hit USTB harder simply because it is more visible.
Pros of Injective
- Diversifying versus USTB with Injective can change portfolio factor exposure.
- Injective can offer higher relative beta when market attention rotates toward its niche.
Cons of Injective
- Trend failures on Injective often travel faster than on more established assets.
- Smaller book depth versus large caps can increase slippage for Injective.
- Incomplete fundamental coverage can hide operational or tokenomic risks.
Which looks stronger right now?
If you weight capitalization and liquidity, USTB looks sturdier; if you weight 24h tape, Injective is ahead. A balanced view treats both as incomplete signals.
AI summary
PEPS synthesizes module output into a readable pair brief. Headline stats put USTB at $1,865.83 and Injective at $5.02. Relative performance over 24h (Injective) is a short window. Pair it with 30d/1y rows before inferring regime change. Return to related comparisons and individual coin intelligence pages to validate whether the relative story still holds after fresh prints.
FAQ
Which is better, USTB or Injective?
“Better” depends on horizon and risk. USTB leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, USTB or INJ?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both USTB and Injective.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.